Comments
Loading...

Celldex Therapeutics

CLDXNASDAQ
Logo brought to you by Benzinga Data
$41.85
0.611.48%
At Close: -
$41.85
00.00%
After Hours: 4:53 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$90.00
Lowest Price Target1
$37.00
Consensus Price Target1
$68.50

Celldex Therapeutics (NASDAQ:CLDX) Stock, Analyst Ratings, Price Targets, Forecasts

Celldex Therapeutics Inc has a consensus price target of $68.5 based on the ratings of 8 analysts. The high is $90 issued by Guggenheim on February 27, 2024. The low is $37 issued by Wells Fargo on August 12, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald on September 18, 2024, September 16, 2024, and September 9, 2024, respectively. With an average price target of $67 between Cantor Fitzgerald, there's an implied 60.10% upside for Celldex Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
May
2
Jun
1
Jul
1
Aug
3
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Wells Fargo
HC Wainwright & Co.
Guggenheim
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Celldex Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Celldex Therapeutics (CLDX) stock?

A

The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by Cantor Fitzgerald on September 18, 2024. The analyst firm set a price target for $67.00 expecting CLDX to rise to within 12 months (a possible 60.10% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Celldex Therapeutics (CLDX)?

A

The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by Cantor Fitzgerald, and Celldex Therapeutics reiterated their overweight rating.

Q

When was the last upgrade for Celldex Therapeutics (CLDX)?

A

The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.

Q

When was the last downgrade for Celldex Therapeutics (CLDX)?

A

There is no last downgrade for Celldex Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

Q

Is the Analyst Rating Celldex Therapeutics (CLDX) correct?

A

While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $67.00 to $67.00. The current price Celldex Therapeutics (CLDX) is trading at is $41.85, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch